Buenavista Equity Partners
Buenavista Equity Partners is the new name of GED Capital following a rebranding announced on October 14, 2024. The independent asset manager's publicly stated Private Equity strategies are Buyout, Healthcare Growth, and Secondaries, with the Buyout strategy focused mainly on the Iberian Peninsula.
What stands out about Buenavista Equity Partners
Buenavista's Buyout strategy seeks majority equity stakes in companies with EBITDA over €3 million and operating margins over 15%. It identifies industrial companies, consumer goods businesses mainly connected to the food value chain, and healthcare products and services as target verticals, and emphasizes growth, Buy&Build, and operational value creation.[1][2][3][5][6]
What does Buenavista Equity Partners invest in?
Buenavista Equity Partners is the new name of GED Capital following a rebranding announced on October 14, 2024. The firm describes itself as an independent asset manager founded in 1996 and operating in the middle-market segment. It operates through Private Equity, Infrastructure, and Venture Capital vehicles.[1][2]
Buenavista’s publicly stated Private Equity strategies are Buyout, Healthcare Growth, and Secondaries. Its Buyout funds invest in middle-market companies and seek to transform them into leaders in their sectors through growth and Buy&Build consolidation strategies.
The firm identifies value-creation levers including organic growth, Buy&Build acquisitions, management professionalisation, digitalisation, ESG policies, operational support, internationalisation, and financial optimisation. Buenavista also states that approximately two-thirds of its recent acquisitions have been proprietary and directly generated.[3]
Owners evaluating a financial buyer can compare the offer with independent valuation analysis, understand how acquirers approach transactions through Auxo’s buy-side M&A process guide, and consider whether a full or partial sale best fits their objectives.
What should a business owner evaluate before considering a transaction with Buenavista Equity Partners?
An owner evaluating Buenavista should clarify the percentage of equity and voting control the firm normally seeks, as well as rollover, governance, and management-incentive arrangements. Other diligence points include current fund deployment periods and reserves for add-on acquisitions, the practical flexibility of EBITDA and margin criteria by sector, and the operating resources assigned to internationalisation, digitalisation, AI adoption, and add-on integration.
The owner should also establish the expected investment horizon and exit-planning process, identify the Buenavista legal entity that would make the investment, and verify which firm-level regulatory registrations or authorisations apply to that entity.[2][3][10]
What percentage of equity and voting control does Buenavista normally seek, and how are rollover, governance, and management-incentive arrangements structured
What are the current fund deployment periods and remaining reserves for add-on acquisitions
How does Buenavista define its target EBITDA and margin thresholds in practice, and how flexible are those criteria by sector
What companies does Buenavista Equity Partners target?
Buenavista’s public Buyout criteria include majority equity stakes in companies with EBITDA over €3 million and operating margins over 15%. The strategy is directed toward middle-market companies and the stated industrial, consumer or food-chain, and healthcare verticals.
Buenavista states that its Buyout funds invest in portfolios of 7-10 companies and do not exceed €30 million per transaction. The B/Buyout III announcement separately states a €250 million target fund size, 8 to 10 platform investments, and an average investment ticket expected to range between €25 million and €30 million.[3][5]
The Buyout strategy identifies industrial companies, consumer goods businesses mainly connected to the food value chain, and healthcare products and services as target verticals.
Healthcare Growth identifies pharmaceuticals and biotechnology, diagnostic solutions, precision medicine and medical devices, AI and Big Data for healthcare, digital therapies and diagnostics, healthcare production projects, CRO/CDMO scientific services, and care services.[3]
Buenavista states that it operates in Europe and has offices in Madrid and Lisbon. Its Buyout strategy invests mainly in the Iberian Peninsula, as does its Healthcare Growth strategy.[3][4]
Buenavista’s Buyout model combines platform investments with Buy&Build acquisitions and sector consolidation. Its stated approach also includes organic growth, operational support, management professionalisation, digitalisation, internationalisation, and financial optimisation.
The public strategy description does not establish specific add-on funding limits, governance arrangements, or integration terms for individual investments. Those points should be clarified for a proposed transaction.[3]
Buenavista’s official portfolio identifies Instituto Bernabeu, a reproductive-medicine business with a presence in Spain and Italy through 10 clinics, and Hundred, a gourmet burger chain identified by the firm as having been awarded the best burger in the world in 2024 and 2025.
The portfolio also identifies Shop&Roll, a designer, manufacturer, and marketer of shopping transport solutions and visual merchandising products operating in more than 80 countries. Other identified healthcare, biotech, telemedicine, AI, imaging, or synthetic-DNA businesses include Highlight Therapeutics, Rofim, PFx Biotech, Omniscope, Quibim, and Syngoi.[6]
Buenavista completed its acquisition of Instituto Bernabeu on May 7, 2026, following relevant competition-authority clearance, and integrated it with Eugin.
Columna Capital signed a binding agreement to acquire a majority interest in Evidenze Group from Buenavista. The agreement date was April 5, 2026, and Buenavista published the announcement on May 6, 2026. Separately, Nexxus Iberia acquired Shop&Roll from Buenavista; Buenavista published that transaction page on April 6, 2026.[7][8][9]
What is not clear from Buenavista Equity Partners's public investment criteria?
The official portfolio page lists portfolio companies and asset descriptions but does not publish acquisition dates, transaction values, ownership percentages, or entry and exit terms for each listed company. The absence of those details on that portfolio page does not establish the terms of any individual transaction.[6]
Questions to ask when evaluating Buenavista Equity Partners as a buyer or investment partner
What percentage of equity and voting control does Buenavista normally seek, and how are rollover, governance, and management-incentive arrangements structured?
What are the current fund deployment periods and remaining reserves for add-on acquisitions?
How does Buenavista define its target EBITDA and margin thresholds in practice, and how flexible are those criteria by sector?
What operating resources are assigned to internationalisation, digitalisation, AI adoption, and add-on integration?
What is the expected investment horizon and exit-planning process for a new platform investment?
Which Buenavista legal entity would make the investment, and what firm-level regulatory registrations or authorisations apply to that entity?
Sources & research notes
- Official website / firm overview
- Official website / firm overview
- Services / capabilities
- Geography / market coverage
- Transaction size / criteria
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Transaction / portfolio evidence
- Structure / regulatory context
How this profile was researched
Auxo profiles are prepared from publicly available primary and authoritative sources and reviewed for entity identity, factual support and disclosure consistency. When a fact cannot be supported by the reviewed public record, the profile identifies it as something to confirm directly rather than inferring it.
Independent research profile
This profile was prepared by Auxo Capital Advisors from publicly available information believed to be reliable and is provided solely for informational and educational purposes. It is not an endorsement, recommendation, ranking, solicitation, or representation regarding the profiled firm, its services, qualifications, transaction experience, regulatory status, financial condition, or suitability for any particular person, company, transaction, or investment.
Information obtained from third-party and public sources may be incomplete, inaccurate, outdated, or subject to change, and Auxo Capital Advisors makes no representation or warranty, express or implied, as to its accuracy, completeness, or timeliness. Readers should conduct their own independent diligence and consult appropriate professional advisers before engaging any advisor, intermediary, investor, lender, acquirer, or other transaction counterparty.
Broker-dealer and securities disclosure
Auxo Capital Advisors is an affiliate of Weild & Co., Member FINRA | SIPC. Securities-related activities and securities transactions are conducted through Weild & Co.
Nothing contained on this page constitutes an offer to sell, an offer to purchase, or a solicitation of an offer to buy or sell any security, investment product, or financial instrument. Nothing on this page constitutes investment advice, a recommendation regarding any security, or a recommendation to enter into any transaction with the profiled firm or any other party.
Any securities transaction, capital-raising engagement, investment-banking engagement, or other securities-related activity involving Auxo Capital Advisors or Weild & Co. is subject to applicable regulatory requirements, internal review and approval, suitability and other applicable diligence requirements, and the terms of a separate written engagement or transaction agreement, as applicable.
Inclusion of a third-party firm in this directory does not imply affiliation with, sponsorship by, endorsement by, or any other relationship with Auxo Capital Advisors or Weild & Co. unless expressly stated otherwise.
